secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0000059478-22-000130
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q1 2022 revenue up 15% to $7.81B; reported EPS $2.10, non-GAAP $2.62; raises guidance
--------------------------------------------------------------------------------

- Revenue $7.81B (+15% YoY); volume growth 20%; core product sales up 13 ppt.
- Reported EPS $2.10 (+41%); non-GAAP EPS $2.62 (+63%); both include $0.15 charges.
- 2022 EPS guidance raised: reported $7.30-$7.45; non-GAAP $8.15-$8.30.
- Tirzepatide SURMOUNT-1 obesity Phase 3: up to 22.5% weight loss; 63% of high-dose group lost ≥20% body weight.
- FDA accepted mirikizumab submission for UC; Jardiance EMPA-KIDNEY trial stopped early for positive efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000130/0000059478-22-000130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000130/lly-20220428.htm
  HTML page:      https://secwatch.observer/filing/0000059478-22-000130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer